The Safety of available immunotherapy for the treatment of glioblastoma.
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Current standard of care involves maximal surgical resection combined with adjuvant chemoradiation. Growing support exists for a role of immunotherapy in treating these tumors with the goal of targeted cytotoxicity. Here we review data on the safety for current immunotherapies being tested in GBM. Areas covered: Safety data from published clinical trials, including ongoing clinical trials were reviewed. Immunotherapeutic classes currently under investigation in GBM include various vaccination strategies, adoptive T cell immunotherapy, immune checkpoint blockade, monoclonal antibodies, and cytokine therapies. Trials include children, adolescents, and adults with either primary or recurrent GBM. Expert opinion: Based on the reviewed clinical trials, the current immunotherapies targeting GBM are safe and well-tolerated with minimal toxicities which should be noted. However, the gains in patient survival have been modest. A safe and well-tolerated combinatory immunotherapeutic approach may be essential for optimal efficacy towards GBM.
['Farber|S Harrison|SH|', 'Elsamadicy|Aladine A|AA|', 'Atik|Ahmet Fatih|AF|', 'Suryadevara|Carter M|CM|', 'Chongsathidkiet|Pakawat|P|', 'Fecci|Peter E|PE|', 'Sampson|John H|JH|']
D000293:Adolescent D000328:Adult D000818:Animals D000911:Antibodies, Monoclonal D001932:Brain Neoplasms D019496:Cancer Vaccines D002648:Child D016207:Cytokines D005909:Glioblastoma D006801:Humans D007167:Immunotherapy
safety immunotherapy Glioblastoma clinical trials adverse events